Search Results for “Customizable SAP E_S4HCON2023 Practice Exam Software 🐂 Easily obtain ➠ E_S4HCON2023 🠰 for free download through ⇛ www.pdfvce.com ⇚ 🛐E_S4HCON2023 Exam Practice” – Page 25

Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA²LEN taskforce position paper

Baiardini, I.+, Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., van Wijk, G. R., La Grutta, S., Lombardi, C., Maurer, M. Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Bom, A. T., Bousquet, J., Zuberbier, T., and Braido, F.: Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: A GA²LEN taskforce position paper. Allergy 2010: 65; 290-295. IF: 6.29

o.090

96	Zuberbier, T.+, Balke, M., Worm, M., Edenharter, G., and Maurer, M.: Epidemiology of urticaria: a representative cross-sectional population survey. Clin. Exp. Dermatol. 2010: 35; 869-873. IF: 1.26

297	Ertaş, R., Ozyurt, K., Atasoy, M., Hawro, T., and Maurer, M.+: The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018: 73; 705-712. IF: 6.77

100	Dölle, S., Hoser, D., Rasche, C., Loddenkemper, C., Maurer, M. Zuberbier, T., and Worm, M.+: Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy 2010: 65; 1158-1165. IF: 6.29

Impaired T-cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome

207

Ngouateu, O. B., Weller, K., Bröhl, K., Kamtchouing, P., Same-Ekobo, A., Dondji, B. , Maurer, M., and Stebut, E.+: Impaired T cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome. Exp. Dermatol. 2015: 24; 302-304. IF: 2.67

o.207

16.	Maurer, M.: Chronic urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M., editors: Urticaria and Angioedema. Heidelberg: Springer, 2010

108	Franzke, N.+, Schäfer, I., Jost, K., Blome, C., Rustenbach, S. J., Reich, K., Reusch, M., Maurer, M. and Augustin, M.: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 2011: 66; 665-670. IF: 6.27

Innate immunity in atopic dermatitis

17.

Mrabet-Dahbi, S. and Maurer, M.: Innate immunity in atopic dermatitis. In: Shiohara T., Amagai, M., Homey, B., Nakanishi, K., Woodfolk, J. A., Bieber, T., Flohr, C., Schittek, B., Hayakawa, J., Yu, H.-S., Oranje, A. P., Schmid-Grendelmeier, P., and Akdis, C. A., editors: Current Problems in Dermatology „Atopic Dermatitis“. Basel: S. Karger Publishers, 2011

386.	Chen, Y.-D., Krause, K., Tu, P., Zhao, Z.⁺, and Maurer, M.⁺: Response of omalizumab in normocomplementemic urticarial vasculitis. J. Allergy Clin. Immunol. Pract. 2020: 8; 2114-2117. IF: 8.86

o.386

345	Krause, K., Sabat, R., Witte-Händel, E., Schulze, A., Puhl, V., Maurer, M., and Wolk, K.+: Association of CCL2 with systematic inflammation in Schnitzler syndrome. Br. J. Dermatol. 2019: 180; 859-868. IF: TBD (IF 2018: 6.71)

Results